Vertex Pharmaceuticals Incorporated (VRTX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
VRTX Revenue Growth
Revenue Breakdown (FY 2025)
VRTX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
VRTX Revenue Analysis (2014–2025)
As of May 6, 2026, Vertex Pharmaceuticals Incorporated (VRTX) generated trailing twelve-month (TTM) revenue of $12.26 billion, reflecting solid growth of +7.8% year-over-year. The most recent quarter (Q1 2026) recorded $2.99 billion in revenue, down 7.4% sequentially.
Looking at the longer-term picture, VRTX's 5-year compound annual growth rate (CAGR) stands at +14.2%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $12.07 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows VRTX's business is primarily driven by TRIKAFTA/KAFTRIO (86%), ALYFTREK (7%), and Manufactured Product, Other (7%). With over half of revenue concentrated in TRIKAFTA/KAFTRIO, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including REGN (+5.9% YoY), ALNY (+82.6% YoY), and BMRN (+9.9% YoY), VRTX has underperformed the peer group in terms of revenue growth. Compare VRTX vs REGN →
VRTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| VRTXCurrent | $12.3B | +7.8% | +14.2% | 39.4% | |
 REGN | $14.3B | +5.9% | +11.0% | 24.9% | |
 ALNY | $3.7B | +82.6% | +49.8% | 13.5% | |
 BMRN | $3.2B | +9.9% | +11.6% | 16.6% | |
 SRPT | $1.9B | +47.1% | +37.9% | 11.5% | |
 RARE | $673M | +20.1% | +19.9% | -79.5% |
VRTX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $12.07B | +9.6% | $10.27B | 85.0% | $4.76B | 39.4% |
| 2024 | $11.02B | +11.7% | $9.49B | 86.1% | $-232,900,000 | -2.1% |
| 2023 | $9.87B | +10.5% | $8.61B | 87.2% | $3.83B | 38.8% |
| 2022 | $8.93B | +17.9% | $7.85B | 87.9% | $4.31B | 48.2% |
| 2021 | $7.57B | +22.1% | $6.67B | 88.1% | $2.78B | 36.7% |
| 2020 | $6.21B | +49.1% | $5.47B | 88.1% | $2.86B | 46.0% |
| 2019 | $4.16B | +36.6% | $3.62B | 86.8% | $1.20B | 28.8% |
| 2018 | $3.05B | +22.5% | $2.64B | 86.6% | $635.1M | 20.8% |
| 2017 | $2.49B | +46.2% | $2.21B | 88.9% | $123.2M | 5.0% |
| 2016 | $1.70B | +64.9% | $1.49B | 87.6% | $9.9M | 0.6% |
Full VRTX Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See VRTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VRTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VRTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVRTX — Frequently Asked Questions
Quick answers to the most common questions about buying VRTX stock.
Is VRTX's revenue growth accelerating or slowing?
VRTX maintains +7.8% revenue growth, in line with its 5-year CAGR of +14.2%. TTM revenue stands at $12.3B. Growth rate remains consistent with historical average.
What is VRTX's long-term revenue growth rate?
Vertex Pharmaceuticals Incorporated's 5-year revenue CAGR of +14.2% reflects the sustained expansion pattern. Current YoY growth of +7.8% is near this long-term average.
How is VRTX's revenue distributed by segment?
VRTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.